Headlines about Intersect ENT (NASDAQ:XENT) have been trending somewhat positive this week, Accern reports. The research group scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intersect ENT earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.8290443378862 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media headlines that may have impacted Accern’s analysis:
Shares of NASDAQ XENT traded down $0.85 during midday trading on Friday, reaching $36.60. 205,207 shares of the stock traded hands, compared to its average volume of 198,607. The company has a market capitalization of $1,090.86, a P/E ratio of -65.36 and a beta of 0.75. Intersect ENT has a one year low of $15.90 and a one year high of $40.00.
Intersect ENT (NASDAQ:XENT) last posted its earnings results on Tuesday, February 27th. The medical equipment provider reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.06. Intersect ENT had a negative return on equity of 14.40% and a negative net margin of 16.99%. The firm had revenue of $29.53 million during the quarter, compared to the consensus estimate of $29.45 million. equities analysts expect that Intersect ENT will post -0.61 EPS for the current fiscal year.
Several equities research analysts recently issued reports on XENT shares. Guggenheim reissued a “buy” rating on shares of Intersect ENT in a report on Thursday, March 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $36.00 price objective on shares of Intersect ENT in a report on Monday, December 11th. JPMorgan Chase raised shares of Intersect ENT from a “neutral” rating to an “overweight” rating in a report on Tuesday, January 2nd. BidaskClub lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Finally, Zacks Investment Research raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $33.38.
In other news, CFO Jeryl L. Hilleman sold 12,833 shares of the firm’s stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $37.66, for a total transaction of $483,290.78. Following the transaction, the chief financial officer now owns 36,265 shares in the company, valued at $1,365,739.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Gwen R. Carscadden sold 10,000 shares of the firm’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $34.35, for a total value of $343,500.00. Following the transaction, the insider now owns 13,856 shares in the company, valued at approximately $475,953.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 153,458 shares of company stock worth $5,377,798. Insiders own 13.70% of the company’s stock.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/04/08/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-intersect-ent-xent-stock-price.html.
About Intersect ENT
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose and throat conditions in the United States. It offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.